Banner Week For Bayer In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - For the third time in a week Bayer released positive news related to Japan, saying Jan. 28 it had received marketing approval from the Ministry of Health, Labor and Welfare for Nexavar (sorafenib) for the treatment of advanced renal cell carcinoma. Four days earlier, the German company had said Nexavar received priority review from MHLW for the treatment of hepatocelluar carcinoma, a larger potential market